Delayed acquisition of Plasmodium falciparum antigen-specific CD4+ T cell responses in HIV-exposed uninfected Malawian children receiving daily cotrimoxazole prophylaxis
© The Author(s) 2016
Received: 4 December 2015
Accepted: 28 April 2016
Published: 10 May 2016
Cotrimoxazole (CTX) prophylaxis, recommended in HIV-exposed uninfected (HEU) children primarily against HIV-related opportunistic infections, has been shown to have some efficacy against Plasmodium falciparum malaria. The effects of CTX prophylaxis on the acquisition of P. falciparum antigen specific CD4+ T cells-mediated immunity in HEU children is still not fully understood.
Peripheral blood was collected from HEU and HIV-unexposed uninfected (HUU) children at 6, 12 and 18 months of age. Proportion of CD4+ T cells subsets were determined by immunophenotyping. P. falciparum antigen-specific CD4+ T cells responses were measured by intracellular cytokine staining assay.
There were no differences in the proportions of naïve, effector and memory CD4+ T cell subsets between HEU and HUU children at all ages. There was a trend showing acquisition of P. falciparum-specific IFN-γ and TNF-producing CD4+ T cells with age in both HUU and HEU children. There was, however, lower frequency of P. falciparum-specific IFN-γ-producing CD4+ T cells in HEU compared to HUU at 6 and 12 months, which normalized 6 months after stopping CTX prophylaxis.
The results demonstrate that there is delayed acquisition of P. falciparum-specific IFN-γ-producing CD4+ T cells in HEU children on daily cotrimoxazole prophylaxis, which is evident at 6 and 12 months of age in comparison to HUU age-matched controls. However, whether this delayed acquisition of P. falciparum-specific IFN-γ-producing CD4+ T cells leads to higher risk to malaria disease remains unknown and warrants further investigation.
In children, repeated exposure to Plasmodium falciparum antigens contributes towards the development of effective immunity that controls parasitaemia and prevents severe and life threatening illness [1, 2]. Evidence from mouse models and experimental human infections suggests that both CD4+ and CD8+ T cells play an important role in protective immunity to P. falciparum malaria [3–6]. T cells directly control the development of pre-erythrocytic Plasmodium stages and also direct the immune responses induced by erythrocytic stages of malaria . During blood stage infection, acute pro-inflammatory cytokine-mediated effector responses from CD4+ T cells can restrict growth of the malaria parasites and reduce risk of clinical disease . Of note, production of IFN-γ, TNF, IL-2, IL-6 and IL-4 has been shown in various ways to play a role in anti-malarial immunity [6, 8–13]. IFN-γ has been proposed as the major mediator of parasite clearance during blood stage infection .
Continuous malaria chemoprophylaxis has been shown to slow down the development of clinical immunity in children leading to an increased risk of disease following disruption or cessation of treatment [15, 16]. Cotrimoxazole (CTX), a potent antibiotic and with strong anti-malarial properties , is recommended for prophylaxis in HIV exposed uninfected (HEU) children in the first 12 months of age, primarily to prevent HIV-related opportunistic infections. Due to its anti-malarial properties, CTX may potentially confer malaria chemoprophylaxis, preventing the natural exposure to P. falciparum and subsequent acquisition of malaria specific immunity.
Although there is now good evidence to show that CTX prevents clinical malaria in children taking it [17, 18], limited data exist on the impact of CTX exposure on development of clinical immunity to malaria following cessation of prophylaxis. Immunological measurements against malaria antigens may provide a useful approach to monitor development of natural immunity to malaria during and following termination of CTX prophylaxis. Of the few studies that have looked at the effect of malaria chemoprophylaxis on both humoral and cellular immune responses during and post prophylaxis, the results have been somehow contradictory with children who had received chemoprophylaxis showing reduced levels of malaria specific antibodies but increased cell mediated immunity [19, 20]. Contrary to studies by Aponte et al.  and Menendez et al. , these earlier studies [19, 20] showed no lasting impairment of the protective immunity as measured by incidence of clinical disease in the year following cessation of chemoprophylaxis indicating that perhaps cell mediated immunity is protective despite lower antibody response.
Since CTX is given to these HEU children primarily as an antibiotic rather malaria chemoprophylaxis, its impact on development of natural immunity to malaria in HEU children needs careful assessment. HEU Malawian children on CTX prophylaxis have reduced magnitude and breadth of IgG antibody responses to distinct P. falciparum merozoite antigens  indicating a lack of exposure to malaria antigens. Given the importance of T cell mediated immunity to malaria and that T cell response to malaria antigens correlates poorly with humoral immune responses [19, 22], this study investigated the effects of CTX prophylaxis on the magnitude of P. falciparum antigen specific CD4+ T cells in HEU children during and after prophylaxis, and compared with aged-matched HIV-unexposed uninfected (HUU) children.
Characteristics of the study area, design and participants have already been described in detail before . Briefly, the study was conducted in Zomba district, Malawi where P. falciparum malaria transmission is stable throughout the year, with P. falciparum prevalence rate of around 27 % . HEU children were recruited from the ART clinic at the Zomba Central Hospital and aged matched HUU children as controls from the communities where HEU children were based. Children who were classified as healthy at the time of recruitment and were not on any medication and were breastfeeding were included in the study. As a national policy for Malawi, daily CTX prophylaxis is given to all HEU children from 6 weeks of age, and all pregnant mothers are put on antiretroviral therapy (ART). Individual written informed consent was obtained from the parents or guardians of all children. The College of Medicine Research Ethics Committee (COMREC) approved this protocol.
Collection and processing of samples
Children were seen every 6 months and at each visit, a total of 3 ml of venous blood was collected. 2 ml in sodium heparin tube for intracellular cytokine assay and 1 ml of in EDTA tubes for immunophenotyping. All immunological assays were conducted blinded to the children’s study group.
Plasmodium falciparum antigens
Cryopreserved laboratory adopted strain of P. falciparum (3D7) was kindly provided by ICMER laboratory, Blantyre, Malawi. For recovery, parasite aliquots were thawed using two sodium chloride thawing solutions: (200 µl of 12 % NaCl and 10 ml of 1.6 % NaCl) and washed twice with 25 ml of protein free medium (RPMI-1640 supplemented with 25 mmol/l HEPES and 40 mg/ml gentamycin), as described elsewhere . Parasite culture to late trophozoite stage was done using standard protocols as previously described .
Level of parasitaemia was estimated based on microscopy of thin smears and parasitaemia level of approximately 5 % was used. Pooled cultures were washed and 1.5 ml of warm protein free medium was added to the red cell pellet followed by 2.5 ml warm gelofosine (Bbraun, Melsungen, Germany). The mixture was then allowed to stand for 20 min at 37 °C and supernatant carefully removed and transferred to a second tube. The mixture was washed and approximately 1 μl of the pellet was collected and parasitaemia determined as previously described . The infected erythrocytes were lysed using saponin lysis procedure as previously described . Protein content was determined by NanoDrop as per manufacturer’s instructions and the lysate stored at −80 °C.
Whole blood (20 μl) was stained with surface markers (CD3 PE, CD4 PerCP and CD8 APC-H7 (all from BD Biosciences, San Jose, CA, USA), CD45RA FITC (BD Pharmingen, San Jose, CA, USA) and CCR7 APC (eBiosciences, San Diego, California) and lysed with 2 ml of 1× FACS lysing solution. After wash, the cells were then acquired on a Cyan ADP flow cytometer (Beckman Coulter) and minimum of 10,000 lymphocytes events was collected per tube during acquisition.
Intracellular cytokine staining
Heparinized whole blood (100 μl) was cultured in 96 U bottom culture plate and incubated with PMA/Ionomycin (10 ng/ml and 100 µg/ml, Sigma-Aldrich, UK), P. falciparum 3D7 schizonts lysate (5 µg/ml) and mycobacterium purified protein derivative (10 µg/ml, Statens Serum Institut, Denmark) in parallel with a non-stimulated background control for 24 h. Harvested cells were stained with surface markersCD3-APC-H7, CD4-PerCP (all from BD Biosciences, San Jose, CA, USA), and CD8-Pacific Orange (Invitrogen™ Life technologies, Carlsbad, CA, USA) and lysed as above. The cells were the permeabilized with 500 μl of 1× BD Cytofix/Cytoperm (BD Cytofix/Cytoperm™, San Diego, California) and then stained with intracellular markers IFN-γ-FITC (BD FastImmune™, San Jose, CA, USA) and TNF-PE (BD Biosciences, San Jose, California) for 30 min. The cells were then acquired as above and minimum of 10,000 CD4+ T cell events were collected per sample. Single stained BD comp beads were processed and acquired in parallel to samples each day and used for compensation. Analysis was conducted using FlowJo software version 9.7.5 (Tree Star Inc., San Carlos, CA, USA).
Statistical analysis and graphical presentation were done using GraphPad Prism 6 (GraphPad, California, USA) and STATA (StataCorp, Texas, USA). A Shapiro–Wilk normality test revealed that all data were non-normally distributed. Mann–Whitney U test was used for comparison CD4+ T cell proportions and frequencies of cytokine producing cells between the study groups at each visit. Background responses generated in the negative control wells were subtracted from responses generated from antigen-stimulation to obtain antigen-specific T cell responses. Differences with P values less than 0.05 were considered significant.
Characteristics of study participants
Demographic characteristics of the study participants
Age of study participants at each visit
Number of children per visit
WBC count, ×103 cells/ml
Total CD4 T cells (%)
Mothers health status
Mother on ART, %
Mother on CTX, %
Proportion of CD4+ T cell subsets in HEU and HUU children at 6 , 12 and 18 months
Frequencies of total cytokine-producing Plasmodium falciparum antigen specific CD4+ T cells in HEU and HUU children
Prevalence of asymptomatic and clinical malaria in HEU and HUU children
To determine whether the delayed acquisition of P. falciparum antigen-specific CD4+ T cells would result in higher prevalence of asymptomatic and clinical malaria in HEU children. The number of children with asymptomatic malaria at each scheduled visit was similar in both groups; 6 months (HEU 3 vs. HUU 6.5 %), 12 months (HEU 6.5 vs. HUU 0 %) and 18 months (HEU 6.7 vs. HUU 7.1 %). The number of HEU and HUU children with at least one episode of clinical malaria at any time of the follow up period was similar between HEU and HUU children (9.1 vs. 12.9 %). There was no evidence of increased prevalence of asymptomatic and clinical malaria in HEU children on CTX prophylaxis compared to HUU age-matched controls, but the study was underpowered to conclusively determine this clinical endpoint.
This study investigated the effect of CTX prophylaxis on the acquisition of P. falciparum antigen specific CD4+ T cells in HEU children. The study findings demonstrate that in the context of unaltered proportions of naïve and memory CD4+ T cell subsets and unimpaired CD4+ T cell IFN-γ and TNF producing function, the frequency of P. falciparum antigen-specific IFN-γ-producing CD4+ T cells was lower in HEU children on CTX prophylaxis compared to HUU age-matched controls. However, this normalized to levels seen in HUU children, 6 months upon CTX prophylaxis cessation.
Phenotypic alterations in the proportions of naive and memory T cell subsets have been observed in HEU children during early life [27, 28]. Consequently, alterations in the numbers or proportions of CD4+ T cell subsets may affect the capacity of antigen specific CD4+ T cell response to infections , leading to an increase in risk of infections in HEU children [30–32]. In this study, there was no difference in proportion of CD4+ T cell subsets in between HEU and HUU children from 6 to 18 months of age indicating that HEU children have normal CD4+ T cell phenotypes, contrary to earlier reports which were done mostly during the pre-ART era [28, 33].
The frequencies of P. falciparum antigen-specific IFN-γ-producing CD4+ T cells in HEU children during the period on CTX prophylaxis was lower in comparison to HUU age-matched controls. However, there was no differences in the mitogen-stimulation or Mycobacterium-specific CD4+ T cells. IFN-γ plays an important role in regulating the protective immune responses against blood stage malaria infection even in the absence of antibody response  and has been shown to be a potential marker of P. falciparum exposure . Similar lower frequencies of P. falciparum specific CD4+ T cells were observed in Ugandan under-five children with lower prior malaria incidence compared to children with higher prior incidence. This observation supports the idea that CTX prophylaxis reduces natural exposure to P. falciparum, resulting in a delayed acquisition of cell-mediated immunity against malaria, which ultimately may result in impaired development of P. falciparum antigen-specific antibody-mediated immunity .
In contrast to previous results in the same population , where antibody responses in HEU children remained low post-CTX prophylaxis reflecting delayed acquisition of antibody responses following CTX prophylaxis, the frequency of P. falciparum antigen-specific IFN-γ-producing CD4+ T cells normalized following cessation of prophylaxis and were comparable to HUU children by 18 months of age. Studies from experimental malaria challenge showed that even a single exposure to malaria induced robust CD4+ T cell responses producing IFN-y that could be detected 14 months post infection in the absence of further exposure. These results might therefore explain the current observation that showed a significant increase in the frequency of IFN-γ producing CD4+ T cells in response to P. falciparum in HEU children after CTX prophylaxis suggesting different patterns in acquisition of humoral and T cell mediated immunity to malaria following CTX prophylaxis.
Due to the importance of the IFN-γ in immunity against malaria, it would be anticipated that delayed acquisition of P. falciparum antigen-specific IFN-γ-producing CD4+ T cells would lead to increase risk to asymptomatic and clinical malaria. Unfortunately, this current study could not gather enough clinical endpoints, as it was observed that the prevalence of parasitaemia and clinical malaria in both HEU and HUU children in the study was much lower than the estimated 27 %. This underpowered the study to conclusively show any clinical endpoint differences attributed to the CTX induced perturbation in P. falciparum-specific immunity between the two study groups. Nevertheless, the study reports an important observation showing delayed acquisition of P. falciparum-specific immunity in HEU children during CTX prophylaxis, which requires further investigation.
The choice of immune responses investigated in the study is not exhaustive, and the authors acknowledge that there are other mechanisms that are equally as important. CD4+ T cells producing other cytokines such IL-2, IL-10 and IL-4 alone or in combination with the studied cytokines have been shown to be associated with protection from malaria [6, 8, 11, 12]. However, IFN-γ and TNF are among the major cytokines shown to be associated with immunity against malaria, hence the study provides valid insight on the effect of CTX prophylaxis on antigen-specific CD4+ T cells immune responses. Secondly, although CD4+ T cells are an important producer of IFN-g, they are not the only cells that produce this important cytokine since macrophages, NK and B cells [36, 37] are also known to be a good source of this cytokine. Furthermore, it would have been ideal to have HEU children not on CTX prophylaxis or to have a subgroup of HEU children on CTX prophylaxis beyond 12 months, but this was deemed unethical and not justifiable within the study setting, hence the study had to be done in line with the national policy for Malawi that requires daily CTX prophylaxis to be given to all HEU children from 6 weeks to 12 months of age.
In conclusion, the study has shown that CTX prophylaxis is associated with delayed acquisition of P. falciparum antigen-specific CD4+ T cells in HEU children. This has potential to increase the risk of malaria infection following cessation of CTX prophylaxis, but this study was not able to conclusively address this hypothesis due to limitations in sample size and the duration of the follow-up period. Future studies should be based on a larger sample size and longer follow up durations to ascertain definitively the impact of CTX prophylaxis mediated delay in anti-malarial immunity on risk to clinical malaria. This is a public health dilemma that needs to be tackled.
Conceived and designed the experiments: HL, KP, WLM, KJ. Performed the experiments: HL. Analysed the data: HL, KCJ. Wrote the paper. HL, KSP, WLM, KCJ. Coordination and clinical work: NM, TG, KSP. All authors read and approved the final manuscript.
The authors thank all study participants and guardians, Zinenani Truwah, Saidon Banda, Joana Nyakureha and the whole study team in Zomba for their support and co-operation during the study. The study was supported by the Malawi Health Research Capacity Strengthening Initiative (HRCSI), a DFID and Wellcome Trust funded programme. This research was also partially funded by Fellowship awards provided by the Consortium for Advanced Research Training in Africa (CARTA) andSouthern Africa Consortium for Research Excellence (SACORE). CARTA has been funded by the Wellcome Trust (UK) (Grant No: 087547/Z/08/Z), the Department for International Development (DfID) under the Development Partnerships in Higher Education (DelPHE), the Carnegie Corporation of New York (Grant No.: B 8606), the Ford Foundation (Grant No: 1100–0399), Google.org (Grant No: 191994), Sida (Grant No.: 54100029) and the Bill and Melinda Gates Foundation (Grant No.: 51228). KCJ is supported by Wellcome Trust (UK) through an Intermediate Fellowship number 10583/Z/14/Z. MLW is supported by a strategic award from the Wellcome Trust.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol. 2006;28:51–60. doi:10.1111/j.1365-3024.2006.00808.x.View ArticlePubMedGoogle Scholar
- Schumacher RF, Spinelli E. Malaria in children. Mediterr J Hematol Infect Dis. 2012;4:e2012073. doi:10.4084/MJHID.2012.073.View ArticlePubMedPubMed CentralGoogle Scholar
- Kimura D, Miyakoda M, Honma K, Shibata Y, Yuda M, Chinzei Y, et al. Production of IFN-gamma by CD4(+) T cells in response to malaria antigens is IL-2 dependent. Int Immunol. 2010;22:941–52. doi:10.1093/intimm/dxq448.View ArticlePubMedGoogle Scholar
- Overstreet MG, Cockburn IA, Chen YC, Zavala F. Protective CD8 T cells against Plasmodium liver stages: immunobiology of an ‘unnatural’ immune response. Immunol Rev. 2008;225:272–83. doi:10.1111/j.1600-065X.2008.00671.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet. 2011;377:1770–6. doi:10.1016/s0140-6736(11)60360-7.View ArticlePubMedGoogle Scholar
- Teirlinck AC, McCall MB, Roestenberg M, Scholzen A, Woestenenk R, de Mast Q, et al. Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. PLoS Pathog. 2011;7:e1002389. doi:10.1371/journal.ppat.1002389.View ArticlePubMedPubMed CentralGoogle Scholar
- Spence PJ, Langhorne J. T cell control of malaria pathogenesis. Curr Opin Immunol. 2012;24:444–8. doi:10.1016/j.coi.2012.05.003.View ArticlePubMedGoogle Scholar
- Artavanis-Tsakonas K, Tongren JE, Riley EM. The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology. Clin Exp Immunol. 2003;133:145–52.View ArticlePubMedPubMed CentralGoogle Scholar
- Berretta F, St-Pierre J, Piccirillo CA, Stevenson MM. IL-2 contributes to maintaining a balance between CD4+ Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection. J Immunol. 2011;186:4862–71. doi:10.4049/jimmunol.1003777.View ArticlePubMedGoogle Scholar
- Freitas do Rosario AP, Langhorne J. T cell-derived IL-10 and its impact on the regulation of host responses during malaria. Int J Parasitol. 2012;42:549–55. doi:10.1016/j.ijpara.2012.03.010.View ArticlePubMedGoogle Scholar
- Gitau EN, Tuju J, Karanja H, Stevenson L, Requena P, Kimani E, et al. CD4 + T cell responses to the Plasmodium falciparum erythrocyte membrane protein 1 in children with mild malaria. J Immunol. 2014;192:1753–61. doi:10.4049/jimmunol.1200547.View ArticlePubMedPubMed CentralGoogle Scholar
- Jagannathan P, Eccles-James I, Bowen K, Nankya F, Auma A, Wamala S, et al. IFNgamma/IL-10 co-producing cells dominate the CD4 response to malaria in highly exposed children. PLoS Pathog. 2014;10:e1003864. doi:10.1371/journal.ppat.1003864.View ArticlePubMedPubMed CentralGoogle Scholar
- Robinson LJ, D’Ombrain MC, Stanisic DI, Taraika J, Bernard N, Richards JS, et al. Cellular tumor necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical Plasmodium falciparum malaria in children from Papua New Guinea. Infect Immun. 2009;77:3033–43. doi:10.1128/iai.00211-09.View ArticlePubMedPubMed CentralGoogle Scholar
- McCall MB, Sauerwein RW. Interferon-gamma–central mediator of protective immune responses against the pre-erythrocytic and blood stage of malaria. J Leukoc Biol. 2010;88:1131–43. doi:10.1189/jlb.0310137.View ArticlePubMedGoogle Scholar
- Aponte JJ, Menendez C, Schellenberg D, Kahigwa E, Mshinda H, Vountasou P, et al. Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med. 2007;4:e242. doi:10.1371/journal.pmed.0040242.View ArticlePubMedPubMed CentralGoogle Scholar
- Menendez C, Kahigwa E, Hirt R, Vounatsou P, Aponte JJ, Font F, et al. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet. 1997;350:844–50. doi:10.1016/s0140-6736(97)04229-3.View ArticlePubMedGoogle Scholar
- Mbeye NM, ter Kuile FO, Davies MA, Phiri KS, Egger M, Wandeler G. Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health. 2014;19:1057–67. doi:10.1111/tmi.12352.View ArticlePubMedPubMed CentralGoogle Scholar
- Davis NL, Barnett EJ, Miller WC, Dow A, Chasela CS, Hudgens MG, et al. Impact of daily cotrimoxazole on clinical malaria and asymptomatic parasitemias in HIV-exposed, uninfected infants. Clin Infect Dis. 2015;61:368–74. doi:10.1093/cid/civ309.View ArticlePubMedGoogle Scholar
- Hogh B, Thompson R, Lobo V, Dgedge M, Dziegiel M, Borre M, et al. The influence of Maloprim chemoprophylaxis on cellular and humoral immune responses to Plasmodium falciparum asexual blood stage antigens in schoolchildren living in a malaria endemic area of Mozambique. Acta Trop. 1994;57:265–77.View ArticlePubMedGoogle Scholar
- Otoo LN, Riley EM, Menon A, Byass P, Greenwood BM. Cellular immune responses to Plasmodium falciparum antigens in children receiving long term anti-malarial chemoprophylaxis. Trans R Soc Trop Med Hyg. 1989;83:778–82.View ArticlePubMedGoogle Scholar
- Longwe H, Jambo KC, Phiri KS, Mbeye N, Gondwe T, Hall T, et al. The effect of daily co-trimoxazole prophylaxis on natural development of antibody-mediated immunity against P. falciparum malaria infection in HIV-exposed uninfected Malawian children. PLoS ONE. 2015;10:e0121643. doi:10.1371/journal.pone.0121643.View ArticlePubMedPubMed CentralGoogle Scholar
- Riley EM, Andersson G, Otoo LN, Jepsen S, Greenwood BM. Cellular immune responses to Plasmodium falciparum antigens in Gambian children during and after an acute attack of falciparum malaria. Clin Exp Immunol. 1988;73:17–22.PubMedPubMed CentralGoogle Scholar
- Okiro EA, Kazembe LN, Kabaria CW, Ligomeka J, Noor AM, Ali D, et al. Childhood malaria admission rates to four hospitals in Malawi between 2000 and 2010. PLoS ONE. 2013;8:e62214. doi:10.1371/journal.pone.0062214.View ArticlePubMedPubMed CentralGoogle Scholar
- Nielsen MA, Staalsoe T, Kurtzhals JA, Goka BQ, Dodoo D, Alifrangis M, et al. Plasmodium falciparum variant surface antigen expression varies between isolates causing severe and nonsevere malaria and is modified by acquired immunity. J Immunol. 2002;168:3444–50.View ArticlePubMedGoogle Scholar
- Trager W, Jensen JB. Human malaria parasites in continuous culture. 1976. J Parasitol. 2005;91:484–6. doi:10.1645/0022-3395(2005)091[0484:hmpicc]2.0.co;2.Google Scholar
- Chilongola J, Balthazary ST, Mbugi EV. Optimization of a protocol for extraction of Plasmodium falciparum RNA from infected whole blood samples for use in DNA microarrays. Afr J Biotechnol. 2008;7:1461–7.Google Scholar
- Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-Jones SL. HIV-exposed uninfected children: a growing population with a vulnerable immune system? Clin Exp Immunol. 2014;176:11–22. doi:10.1111/cei.12251.View ArticlePubMedPubMed CentralGoogle Scholar
- Ono E, Nunes dos Santos AM, de Menezes Succi RC, Machado DM, de Angelis DS, Salomao R, et al. Imbalance of naive and memory T lymphocytes with sustained high cellular activation during the first year of life from uninfected children born to HIV-1-infected mothers on HAART. Braz J Med Biol Res. 2008;41:700–8.View ArticlePubMedGoogle Scholar
- Kakkar F, Lamarre V, Ducruet T, Boucher M, Valois S, Soudeyns H, et al. Impact of maternal HIV-1 viremia on lymphocyte subsets among HIV-exposed uninfected infants: protective mechanism or immunodeficiency. BMC Infect Dis. 2014;14:236. doi:10.1186/1471-2334-14-236.View ArticlePubMedPubMed CentralGoogle Scholar
- Koyanagi A, Humphrey JH, Ntozini R, Nathoo K, Moulton LH, Iliff P, et al. Morbidity among human immunodeficiency virus-exposed but uninfected, human immunodeficiency virus-infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy. Pediatr Infect Dis J. 2011;30:45–51. doi:10.1097/INF.0b013e3181ecbf7e.View ArticlePubMedGoogle Scholar
- Marinda E, Humphrey JH, Iliff PJ, Mutasa K, Nathoo KJ, Piwoz EG, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J. 2007;26:519–26. doi:10.1097/01.inf.0000264527.69954.4c.View ArticlePubMedGoogle Scholar
- Slogrove A, Reikie B, Naidoo S, De Beer C, Ho K, Cotton M, et al. HIV-exposed uninfected infants are at increased risk for severe infections in the first year of life. J Trop Pediatr. 2012;58:505–8. doi:10.1093/tropej/fms019.View ArticlePubMedPubMed CentralGoogle Scholar
- Miyamoto M, Pessoa SD, Ono E, Machado DM, Salomao R, Succi RC, et al. Low CD4 + T-cell levels and B-cell apoptosis in vertically HIV-exposed noninfected children and adolescents. J Trop Pediatr. 2010;56:427–32. doi:10.1093/tropej/fmq024.View ArticlePubMedPubMed CentralGoogle Scholar
- Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet. 2002;360:610–7. doi:10.1016/s0140-6736(02)09784-2.View ArticlePubMedGoogle Scholar
- Riley EM, Morris-Jones S, Blackman MJ, Greenwood BM, Holder AA. A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission. Parasite Immunol. 1993;15:513–24.View ArticlePubMedGoogle Scholar
- Bao Y, Liu X, Han C, Xu S, Xie B, Zhang Q, et al. Identification of IFN-gamma-producing innate B cells. Cell Res. 2014;24:161–76. doi:10.1038/cr.2013.155.View ArticlePubMedPubMed CentralGoogle Scholar
- Frucht DM, Fukao T, Bogdan C, Schindler H, O’Shea JJ, Koyasu S. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 2001;22:556–60.View ArticlePubMedGoogle Scholar